The information contained within this
announcement is deemed to constitute inside information as
stipulated under the Market Abuse Regulations (EU) No. 596/2014,
which is part of UK law by virtue of the European Union
(Withdrawal) Act 2018. Upon the publication
of this announcement, this inside information is now considered to
be in the public domain.
25 March 2024
ONDINE BIOMEDICAL INC.
("Ondine Biomedical",
"Ondine", or the "Company")
First commercial adoption of
Steriwave by the NHS
NHS deal gives patients access to
groundbreaking light-activated antimicrobial to combat AMR
(antimicrobial resistance)
· A new light-activated
antimicrobial that kills all types of bugs - viruses, bacteria, and
fungi - in minutes without generating resistance is being adopted
by two NHS hospitals to reduce surgical infections.
Mid Yorkshire Teaching NHS Trust has approved the
commercial adoption of Ondine's groundbreaking light-activated
antimicrobial, Steriwave®. The approval will see the use of
Steriwave expanded across hip and knee surgery patients at
Pontefract and Pinderfields NHS Hospitals to reduce the incidence
of surgical site infections (SSIs). This adoption as
standard-of-care for orthopedic patients follows a successful,
initial deployment that is being used to evaluate Steriwave at
Pontefract Hospital.
Dr Stuart Bond, Consultant antimicrobial pharmacist
and Director of Innovation at Mid Yorkshire Teaching NHS Trust,
commented:
"We are very pleased to be the first NHS Trust to be
giving patients access to this important new technology. SSIs can
have a devastating effect on patients and their families, and we
are pleased that we have demonstrated the feasibility of using
Steriwave in our Orthopaedic Centre of Excellence at Pontefract
Hospital. It is a real step forward to making Steriwave more widely
available across the Trust."
The CEO of Ondine Biomedical, a world leader in
light-activated antimicrobial technology, Carolyn Cross, said:
"We are delighted to see the first two NHS hospitals
adopt Steriwave, particularly as NHS is seen around the world as a
leader in antibiotic stewardship in response to the growing threat
of AMR (antimicrobial resistance). This is not only a significant
milestone for Ondine, but Mid Yorks's accelerated decision to adopt
suggests that Steriwave has been well received by patients,
surgeons, and nurses."
As announced on 5 March 2024, Ondine Biomedical, Mid
Yorkshire Teaching NHS Trust, and Health Innovation Yorkshire &
Humber have partnered to sponsor a health economic analysis with
the York Health Economics Consortium (YHEC). The full findings of
this study [are expected to be reported on later this year and]
will be used to support the further spread and adoption of
Steriwave across the NHS and across additional surgical
applications.
SSIs are one of the most common healthcare-associated
infections (HAIs) and affect one in every 20 patients who undergo a
surgical procedure in the NHS.[1] SSIs can cost up to £100,000
per patient,[2] and the overall cost of HAIs to
NHS England is over £2 billion a year.[3] These costs are expected to
rise as growing rates of antimicrobial resistance (AMR) make the
current standard of care - the antibiotic mupirocin - less
effective.[4]
Steriwave is a light-activated antimicrobial that
uses a specific wavelength of red light to destroy pathogens that
colonise the nose and can spread to cause harmful infections.
Crucially, unlike traditional antibiotics, Steriwave is immediately
effective with a single five-minute treatment and does not trigger
antimicrobial resistance (AMR). Nasal decolonization - eliminating
harmful pathogens from the nasal cavities - is recommended by WHO
and NICE prior to surgery as a key approach to preventing
SSIs.[5]
Steriwave has been used in over 150,000 patient
treatments, including at major hospitals across Canada, including
Vancouver General Hospital (VGH), The Ottawa Hospital (TOH), and
the Mazankowski Alberta Heart Institute. Research recently
published by VGH in the Canadian Journal of Surgery showed that the
use of Steriwave in patients undergoing spine surgery resulted in a
66.5% reduction in post-surgical infection rates and almost $2600
per spine surgery patient, representing $2.5 million in annual
savings for Vancouver General Hospital's spine group.[6] No serious
adverse events have ever been reported from Steriwave
treatment.
**ENDS**
Enquiries:
Ondine Biomedical
Inc.
|
|
Carolyn Cross,
CEO
|
+001 (604) 665 0555
|
Singer Capital Markets (Nominated Adviser and Joint
Broker)
|
|
Aubrey Powell, Asha Chotai, Sam
Butcher
|
+44 (0)20 7496 3000
|
RBC
Capital Markets (Joint Broker)
|
|
Rupert Walford, Kathryn
Deegan
|
+44 (0)20 7653 4000
|
Vane Percy & Roberts (Media Contact)
|
|
Simon Vane Percy, Amanda
Bernard
|
+44 (0)77 1000 5910
|
About Ondine
Biomedical Inc.
Ondine Biomedical Inc. is a Canadian life science
company and a world leader in the development and clinical use of
light-activated antimicrobial therapies (also known as
'photodisinfection'). Based on its proprietary light-activated
technology, Ondine has a pipeline of investigational products in
various stages of development.
Ondine's nasal decolonisation light-activated
technology has a CE mark in Europe and the UK and is approved in
Canada and several other countries under the name Steriwave®. In
the US, it has been granted Qualified Infectious Disease Product
designation and Fast Track status by the FDA and is currently
undergoing clinical trials for regulatory approval. Light-activated
antimicrobial products in development include therapies for a
variety of medical indications such as chronic sinusitis,
ventilator-associated pneumonia, burns, and other indications.
About
Steriwave®
Ondine's Steriwave is a patented technology using a
proprietary light-activated antimicrobial (photosensitizer) to
destroy bacteria, viruses, and fungi colonizing the nose - a major
reservoir of pathogens. The treatment is carried out by a trained
healthcare professional and is an easy-to-use, painless, two-step
process. The photosensitizer is applied to each nostril using
a nasal swab, followed by illumination of the area with a specific
wavelength of red light for less than five minutes. The light
activates the photosensitizer, causing an oxidative burst that is
lethal to all types of pathogens without causing long-term adverse
effects on the nasal microbiome. A key benefit of this approach,
unlike with antibiotics, which have resistance
rates reported as high as 81%[7], is
that pathogens do not develop resistance to the therapy.
Nasal decolonization is recommended in the 2016 WHO
Global guidelines for the prevention of surgical site
infections,[8] and the Society for
Healthcare Epidemiology of America (SHEA) guidelines, published in
May 2023, recommend nasal decolonisation for major surgical
procedures.[9]
[1] National Institute for
Health and Care Excellence, Surgical site infections: prevention
and treatment NICE guideline [NG125], 2019,
https://www.nice.org.uk/guidance/ng125/chapter/Context)
[2] Getting it Right First
Time, SSI National Survey, April 2019,
https://gettingitrightfirsttime.co.uk/wp-content/uploads/2017/08/SSI-Report-GIRFT-APRIL19e-FINAL.pdf)
[4] Naylor NR, Evans S,
Pouwels KB, Troughton R, Lamagni T, Muller-Pebody B, Knight GM,
Atun R, Robotham JV. Quantifying the primary and secondary effects
of antimicrobial resistance on surgery patients: Methods and data
sources for empirical estimation in England. Front Public Health.
2022 Aug 8;10:803943. doi: 10.3389/fpubh.2022.803943. PMID:
36033764; PMCID: PMC9413182.
[6] Eryck Moskven, Daniel
Banaszek, Eric C. Sayre, Aleksandra Gara, Elizabeth Bryce, Titus
Wong, Tamir Ailon, Raphaële Charest-Morin, Nicolas Dea, Marcel F.
Dvorak, Charles G. Fisher, Brian K. Kwon, Scott Paquette and John
T. Street. Can J Surg November 15, 2023 66 (6) E550-E560; DOI:
https://doi.org/10.1503/cjs.016922
[7] Poovelikunnel T, Gethin G, Humphreys H. Mupirocin resistance:
clinical implications and potential alternatives for the
eradication of MRSA. J Antimicrob Chemother.
2015;70(10):2681-2692. doi:10.1093/jac/dkv169
[9] Calderwood MS, Anderson DJ, Bratzler DW, et al. Strategies to
prevent surgical site infections in acute-care hospitals: 2022
Update. Infect Control Hosp Epidemiol. 2023;44(5):695-720.
doi:10.1017/ice.2023.67